Menta Capital’s Lipocine LPCN Stock Holding History

Menta Capital’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-799	Closed	-$176K	–	973
2015 Q4	$176K	Buy	799 +146	+22%	+$30.6K	0.02%	784
2015 Q3	$131K	Buy	+653	New	+$151K	0.02%	664

Other funds holding LPCN

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Menta Capital's LPCN Position: Q1 2016 in Review

Menta Capital sold out of Lipocine (LPCN) in Q1 2016, closing a stake of 799 shares — an estimated $176K sold.

Menta Capital first reported a position in LPCN in Q3 2015 and held it in 2 quarters. The position peaked at $176K in Q4 2015. 53 funds tracked by Wall St. Rank hold LPCN as of Q1 2016.

Menta Capital reported no remaining Lipocine position as of Q1 2016 after selling out during the quarter.
Menta Capital sold 799 Lipocine shares in Q1 2016, an estimated $176K.
Menta Capital first reported a position in Lipocine in Q3 2015 and held it in 2 quarters.
Menta Capital's Lipocine position peaked at $176K in Q4 2015.
53 funds tracked by Wall St. Rank held Lipocine as of Q1 2016.

Based on Menta Capital's 13F filing for Q1 2016, filed 11 May 2016.